Publications

Gawade PL, Li S, Henry D, Smith N, Belani R, Kelsh MA, et al. Patterns of granulocyte colony-stimulating factor prophylaxis in patients with cancer receiving myelosuppressive chemotherapy. 2020. Support Care Cancer 28(9):4413–4424.

Gawade PL, Li S, Henry D, Smith N, Belani R, Kelsh MA, et al. Patterns of granulocyte colony-stimulating factor prophylaxis in patients with cancer receiving myelosuppressive chemotherapy. 2020. Support Care Cancer 28(9):4413–4424.

Hawkins A, Murphy A, McNamara M, Gawade PL, Belani R, Kelsh MA. A survey of oncologists’ perceptions and opinions regarding the use of granulocyte colony-stimulating factors. 2020. J Cancer Edu 35(1):178–186.

Hawkins A, Murphy A, McNamara M, Gawade PL, Belani R, Kelsh MA. 2020. A survey of oncologists’ perceptions and opinions regarding the use of granulocyte colony-stimulating factors. J Cancer Edu 35(1):178–186.

Locatelli F, Whitlock JA, Peters C, Chen-Santel C, Chia V, Dennis RM, … Kelsh MA, et al. 2020. Blinatumomab versus historical standard therapy in pediatric patients with relapsed/refractory Ph-negative B-cell precursor acute lymphoblastic leukemia. Leukemia 34(9):2473–2478; doi: 10.1038/s41375-020-0770-8. PMID: 32094465.

Ravandi F, Pierce S, Garcia-Manero G, Kadia T, Jabbour E, Borthakur G, … Kelsh M, et al. 2020. Salvage therapy outcomes in a historical cohort of patients with relapsed or refractory acute myeloid leukemia. Clin Lymphoma Myeloma Leuk 20(11):e871–e882.

Gage SM, Reichert H. 2020. Determining the incidence of needle-related complications in hemodialysis access: We need a better system. J Vascular Access 22(4)521-532; doi: 10.1177/1129729820946917.

Thompson CM, Donahue DA, Hobbs C, Costecalde Y, Franzen A, Suh M, Proctor DM, Harris MA. 2020. Exposure to environmentally-relevant concentrations of hexavalent chromium does not induce ovarian toxicity in mice. Regul Toxicol Pharmacol 116:104729; doi: 10.1016/j.yrtph.2020.104729.

Jensen IS, Hathway J, Cyr PL, Gauden D, Gardiner P. 2020. Cost–consequence analysis of ¹⁸F-fluciclovine for the staging of recurrent prostate cancer. J Mark Access Health Pol 8(1):1749362; doi: 10.1080/20016689.2020.1749362.

Hathway J, Miller-Wilson L, Jensen I, Ozbay B, Regan C, Jena A, et al. 2020. Projecting total costs and health consequences of increasing mt-sDNA utilization for colorectal cancer screening from the payer and integrated delivery network perspectives. J Med Econ 23(6):581-592; doi: 10.1080/13696998.2020.1730123.